Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In India, June Was An Odd Month As Sales Disappointed But Future Looks Bright

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - For the thousands of medical representatives in India chasing aggressive targets, June is a critical month as it marks the start of the monsoon season. Monsoons last four months as heavy rains lead to a surge in cases of infectious diseases, diarrhea, asthma and respiratory issues. Sales of medicines as such are remarkably higher in these months compared to the rest of the year. But this year, June has been an odd and rather disappointing month, with sales growing at just 12.6%, down almost 2% from May which showed a growth of 14.5%

You may also be interested in...



Extended Monsoons Help Pep Up Sales In India; Anti-infectives Show Revival In August

MUMBAI - Heavy monsoon rains during the month of August helped the Indian pharmaceutical industry revive from its sagging July sales as the anti-infectives market showed signs of picking up momentum

Extended Monsoons Help Pep Up Sales In India; Anti-infectives Show Revival In August

MUMBAI - Heavy monsoon rains during the month of August helped the Indian pharmaceutical industry revive from its sagging July sales as the anti-infectives market showed signs of picking up momentum

India's Sales Rankings Shuffle As IMS Health Widens Audit To Hospitals And Doctors

MUMBAI - GlaxoSmithKline PLC gained the top sales slot in India with Augmentin (amoxicillin/clavulanate) as a result of data analysis firm IMS Health expanding its sales audit coverage in the country

Latest Headlines
See All
UsernamePublicRestriction

Register

SC078486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel